Secondary Logo

Institutional members access full text with Ovid®

Epstein–Barr virus biomarkers have no prognostic value in HIV-related Hodgkin lymphoma in the modern combined antiretroviral therapy era

Lupo, Juliena; Germi, Raphaëlea; Lancar, Rémib; Algarte-Genin, Michèleb; Hendel-Chavez, Houriac; Taoufik, Yassined; Mounier, Nicolase; Partisani, Marialuisaf; Bonnet, Fabriceg; Meyohas, Marie-Carolineh; Marchou, Brunoi; Semanova, Touyanaa; Prevot, Sophiej; Costagliola, Dominiqueb; Morand, Patricea,*; Besson, Carolinek,*

doi: 10.1097/QAD.0000000000002129
CLINICAL SCIENCE
Buy
SDC

Objectives: Epstein–Barr virus (EBV) has been implicated in lymphomagenesis of HIV-related classical Hodgkin lymphoma (HIV-cHL). The utility of EBV molecular and serological biomarkers has scarcely been examined in HIV-cHL in the recent combined antiretroviral therapy (cART) era.

Design: We evaluated EBV DNA load and a panel of EBV antibodies in HIV-cHL patients prospectively enrolled in the French ANRS-CO16 Lymphovir cohort between 2008 and 2015.

Methods: Pretreatment whole blood, plasma EBV DNA load and serological profiles were analysed in 63 HIV-infected patients diagnosed with cHL. For the 42 patients with available material, comparisons were performed between values at diagnosis and 6 months after the initiation of chemotherapy.

Results: Pretreatment whole blood and plasma EBV DNA loads were positive in 84 and 59% of HIV-cHL patients, respectively. Two-year progression-free survival estimates did not differ between the patients with pretreatment whole blood (n = 53) or plasma (n = 37) EBV DNA(+) and the patients with pretreatment whole blood (n = 10) or plasma (n = 26) EBV DNA(−) (92 vs. 80% or 89 vs. 92%, P = 0.36 and 0.47, respectively). At diagnosis, 47% of patients harboured an EBV reactivation serological profile. Following chemotherapy, whole blood and plasma EBV DNA levels significantly declined from medians of 1570 [interquartile range, 230–3760) and 73 (0–320) copies/ml to 690 (0–1830) and 0 (0–0) copies/ml, respectively (P = 0.02 and P < 0.0001, respectively]. Anti-EBV IgG antibody level significantly dropped at 6-month follow-up (P = 0.004).

Conclusion: Whole blood and plasma EBV DNA loads do not constitute prognostic markers in HIV-cHL patients in the modern cART era.

aInstitut de Biologie Structurale (IBS), CEA, CNRS, Université Grenoble-Alpes; Laboratoire de Virologie, Centre hospitalier Universitaire Grenoble-Alpes, Grenoble

bINSERM, Sorbonne Université, Institut Pierre Louis d’Epidémiologie et de Santé Publique (IPLESP)

cAP-HP, Hôpitaux Paris Sud, Service d’Immunologie biologique

dINSERM U1184, Center for Immunology of Viral Infections and Autoimmune Diseases; Université Paris Sud; AP-HP Hôpitaux Paris Sud, Service d’Immunologie biologique, Le Kremlin-Bicêtre, Paris

eDépartement d’Hémato-Oncologie, Archet Hospital, Nice

fHôpitaux Universitaires, Centre de soins de l’infection VIH, Strasbourg

gCHU Bordeaux, Service de Médecine Interne et Maladies Infectieuses; INSERM U593, Université de Bordeaux, Bordeaux

hAP-HP CHU Saint-Antoine, Service de maladies infectieuses, Paris

iCHU Toulouse, Service de maladies infectieuses, Toulouse

jAP-HP, Hôpitaux Paris Sud Site Béclère, Service d’anatomo-pathologie; Université Paris Sud, Le Kremlin-Bicêtre

kINSERM U1184, Center for Immunology of Viral Infections and Autoimmune Diseases, Le Kremlin Bicêtre; Unité d’Hémato-Oncologie, Centre Hospitalier de Versailles, Le Chesnay, France; Université Versailles Saint Quentin en Yvelines, Université Paris-Saclay, Paris, France.

Correspondence to Julien Lupo, Dr Laboratoire de Virologie, Centre hospitalier Universitaire de Grenoble, CS 10217, 38043 Grenoble cedex 9, France. Tel: +33476766613; fax: +33476765228; e-mail: jlupo@chu-grenoble.fr; Dr Caroline Besson, MD, PhD, Department of Hematology, Centre Hospitalier de Versailles, 177, rue de Versailles, 78150 LE Chesnay, France. Tel: +33 1 39 63 85 11; fax: +33 1 39 63 94 08; e-mail: cbesson@ch-versailles

Received 21 September, 2018

Revised 6 December, 2018

Accepted 7 December, 2018

Supplemental digital content is available for this article. Direct URL citations appear in the printed text and are provided in the HTML and PDF versions of this article on the journal's Website (http://www.AIDSonline.com).

Copyright © 2019 Wolters Kluwer Health, Inc.